Increased expression of transforming growth factor-β and eosinophil infiltration is associated with the development of transplant arteriosclerosis in long-term surviving cardiac allografts

Transplantation

Volumn 76, Issue 7, 2003, Pages 1105-1111

  Spriewald, Bernd M ^a   Ensminger, Stephan M ^a   Billing, J Stephen ^a   Morris, Peter J ^a   Wood, Kathryn J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CD40 LIGAND; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CONTROLLED STUDY; EOSINOPHIL; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ANIMALS; ANTIBODIES; ANTIGENS, CD4; ARTERIOSCLEROSIS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CELL DIVISION; CYTOKINES; EOSINOPHILS; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERLEUKIN-4; ISOANTIGENS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MYOCARDIUM; TIME FACTORS; TISSUE DONORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HOMOLOGOUS;

EID: 0142135354     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hertz M, Taylor D, Trulock E, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002; 21(9): 950.
2. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14(4): 387.
3. Womer KL, Lee RS, Madsen JC, et al. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci 2001; 356(1409): 727.
4. Van Maurik A, Wood KJ, Jones ND. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway. Transplantation 2002; 74(5): 740.
5. Ensminger SM, Spriewald BM, Sorensen HV, et al. Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of cd40-cd154 costimulation. J Immunol 2001; 167(1): 532.
6. Wood KJ, Jones ND, Bushell AR, et al. Alloantigen-induced specific immunological unresponsiveness. Philos Trans R Soc Lond B Biol Sci 2001; 356(1409): 665.
7. Wong W, Morris PJ, Wood KJ. Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression. Transplantation 1997; 63(10): 1490.
8. Kingsley CI, Karim M, Bushell AR, et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168(3): 1080.
9. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16(4): 343.
10. Bushell A, Niimi M, Morris PJ, et al. Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J Immunol 1999; 162(3): 1359.
11. Ensminger SM, Billing JS, Morris PJ, et al. Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Lung Transplant 2000; 19(11): 1039.
12. Niimi M, Hara M, Witzke O, et al. Donor resting B cells induce indefinite prolongation of fully allogeneic cardiac grafts when delivered with antiimmunoglobulin-D monoclonal antibody: evidence for tolerogenicity of donor resting B cells in vivo. Transplantation 1998; 66(12): 1786.
13. Reiner SL, Zheng S, Corry DB, et al. Constructing polycompetitor cDNAs for quantitative PCR. J Immunol Methods 1993; 165(1): 37.
14. Cuturi MC, Josien R, Cantarovich D, et al. Decreased anti-donor major histocompatibility complex class I and increased class II alloantibody response in allograft tolerance in adult rats. Eur J Immunol 1994; 24(7): 1627.
15. Josien R, Douillard P, Guillot C, et al. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest 1998; 102(11): 1920.
16. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69(9): 1759.
17. Shittu EA, Yang CP, Roberts IS, et al. Inhibition of chronic vascular rejection by donor-specific blood transfusion is associated with a reduction in transforming growth factor-befa1 expression. Transplantation 2002; 73(10): 1573.
18. Sun W, Wang Q, Zhang L, et al. TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo. J Mol Med 2002; 80(8): 514.
19. Hongwei W, Nanra RS, Stein A, et al. Eosinophils in acute renal allograft rejection. Transpl Immunol 1994; 2(1): 41.
20. Goldman M, Le Moine A, Braun M, et al. A role for eosinophils in transplant rejection. Trends Immunol 2001; 22(5): 247.
21. Le Moine A, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 1999; 103(12): 1659.
22. Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol 1994; 94(6 Pt 2): 1183.
23. Punch JD, Tono T, Qin L, et al. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement. J Immunol 1998; 161(3): 1156.
24. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72(7): 1181.
25. Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993; 55(6): 1409.
26. Russell PS, Chase CM, Winn HJ, et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152(10): 5135.
27. Hancock WW, Buelow R, Sayegh MH, et al. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4(12): 1392.
28. Hosenpud JD, Everett JP, Morris TE, et al. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation 1995; 92(2): 205.
29. Chow LH, Huh S, Jiang J, et al. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 1996; 94(12): 3079.
30. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53(3): 550.
31. Dunn MJ, Crisp SJ, Rose ML, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339(8809): 1566.
32. Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999; 60(9): 826.
33. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104(25): 3091.